Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MedCap ABOSTO:MCAP +3.27%95 3-Year EBITDA Growth Rate is 22.20% as of Jun. 2026, which is 8% below its 10-year median of 24.20. GuruFocus rates OSTO:MCAP with a GF Score™ of 95/100 and a GF Value™ of kr572.68 (Fairly Valued). The stock has 1 warning sign investors should review. Among 688 Medical Devices & Instruments companies, MedCap AB ranks better than 68.46% on this metric.
During the past 12 months, MedCap AB's average EBITDA Per Share Growth Rate was 34.00% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 22.20% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 24.00% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 30.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of MedCap AB was 68.50% per year. The lowest was -21.70% per year. And the median was 24.20% per year.
MedCap AB (OSTO:MCAP) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
MedCap AB 3-Year EBITDA Growth Rate Related Terms
OSTO:MCAP vs ABT, SYK, MDT: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, MedCap AB's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MedCap AB 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, MedCap AB's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where MedCap AB's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 22.20% mean?
MedCap AB (OSTO:MCAP) has a 3-Year EBITDA Growth Rate of 22.20% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for MedCap AB and its competitors. This is near median its historical median of 24.20. According to the industry distribution chart, MedCap AB ranks #217 out of 688 companies in the Medical Devices & Instruments industry, placing it in the top 31.5%.
Is MedCap AB's 3-Year EBITDA Growth Rate too high?
MedCap AB's current 3-Year EBITDA Growth Rate of 22.20% is near median its 10-year median of 24.20. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 7.90. MedCap AB's value of 22.20% is 181% above this industry median. Based on the distribution chart, MedCap AB ranks #217 out of 688 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, MedCap AB has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does MedCap AB's 3-Year EBITDA Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, MedCap AB ranks #217 out of 688 companies for 3-Year EBITDA Growth Rate. This puts MedCap AB in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 7.90. MedCap AB's value of 22.20% is 181% above this benchmark. While the company's 10-year median is 24.20 vs. the industry median of 7.90, MedCap AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 7.90, based on 688 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MedCap AB's current 3-Year EBITDA Growth Rate of 22.20% is 181% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for MedCap AB and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MedCap AB's current 3-Year EBITDA Growth Rate is 22.20%, which is near median its own 10-year median of 24.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedCap AB stock overvalued right now?
Based on GuruFocus' analysis, MedCap AB (OSTO:MCAP) is currently considered Fairly Valued. The stock's GF Value™ is kr572.68, compared to a current price of kr568.50 — trading 0.7% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 22.20%, which is near median its 10-year median of 24.20 and 181% above the Medical Devices & Instruments industry median of 7.90. MedCap AB's overall GF Score™ is 95/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For MedCap AB (OSTO:MCAP), the current 3-Year EBITDA Growth Rate is 22.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MedCap AB (OSTO:MCAP) Overvalued in 2026?
Based on GuruFocus' analysis, MedCap AB stock appears to be undervalued.
The current stock price of kr568.50 is trading 0.7% below its estimated GF Value™ of kr572.68.
GuruFocus considers MedCap AB to be Fairly Valued.
Key valuation signals for OSTO:MCAP:
3-Year EBITDA Growth Rate: 22.20% (near median its 10-year median of 24.20)
GF Value™: kr572.68 vs. price of kr568.50 (0.7% below fair value)
Industry Position: 181% above the Medical Devices & Instruments median (#217 of 688)
No single metric tells the full story. See the OSTO:MCAP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MedCap AB acquires and develops profitable, market-leading niche companies in the Nordic life science industry. It is diversified into two business areas namely Medical technology and Specialist medicines. Medical Technology mainly develops and sells various medical technology products and services. Its Specialist medicines develop and sell medicines within the regulatory classes of registered, extemporaneous and licensed medicines.
95GF Score
Get the complete analysis for OSTO:MCAP
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:MCAP has been successfully added to your 
